REACH InsightsDanielle Drayton2026-05-20T17:50:49+00:00

REACH Insights

Systemic Lupus Erythematosus (SLE): A Market in Transition

February 27th, 2026|

The Disease-Modifying Era in Angelman Syndrome

February 26th, 2026|

The Unyielding Unmet Need in Huntington’s: Why Pipeline Progress is Redefining Therapeutic Strategy

February 25th, 2026|

Why Tissue Type Matters Most in the Next Phase of DM1 Therapeutics

February 24th, 2026|

Systemic Lupus Erythematosus (SLE): A Market in Transition

Danielle Drayton2026-03-24T16:11:20+00:00February 27th, 2026|

The Disease-Modifying Era in Angelman Syndrome

Melissa Curran2026-02-26T20:10:16+00:00February 26th, 2026|

The Unyielding Unmet Need in Huntington’s: Why Pipeline Progress is Redefining Therapeutic Strategy

Melissa Curran2026-02-25T13:58:53+00:00February 25th, 2026|

Why Tissue Type Matters Most in the Next Phase of DM1 Therapeutics

Melissa Curran2026-02-24T18:36:26+00:00February 24th, 2026|

Previous 123 Next